Archive · 18 Jan 2026
Medsource Ozone Explores Funding for Expansion
Medsource Ozone Biomedicals, a company that makes tools and supplies for medical testing, is looking for new investors to help it grow.
They want to raise between ₹300-400 crore and plan to become a much bigger company in the next few years.
This is their second time looking for outside money, and they hope to use it to make more products and sell them in more places.
The company is one of the largest in India for this type of product, and they think the market for medical devices in India will grow a lot in the future.
Medsource Ozone Biomedicals is exploring funding options with EY to raise ₹300-400 crore for expansion.
The company aims to reach ₹500 crore in revenue over the next 3-4 years.
This would be their second external funding round in over four years.
Medsource last raised ₹35 crore from Xponentia Capital Partners in 2021.
The Indian med-tech market is projected to grow significantly, with EY estimating it to reach $50 billion by 2030.
- Who
- Medsource Ozone Biomedicals, a manufacturer of in-vitro diagnostics instruments and reagents
- What
- Hiring EY to explore funding options for expansion
- When
- Details not specified, but planning for the next 3-4 years
- Where
- Faridabad, India
- Why
- To fund expansion and reach ₹500 crore revenue mark
- Company
- Medsource Ozone Biomedicals
- Location
- Faridabad, India
- Revenue (FY24)
- ₹173 crore
- Target Revenue
- ₹500 crore in 3-4 years
- Funding Goal
- ₹300-400 crore
- Advisor
- Ernst & Young (EY)
- Last Funding
- ₹35 crore from Xponentia Capital Partners in 2021
- Key Products
- Testing instruments, rapid test kits, reagents